Adam Martin

[Stephen V Liu, MD @StephenVLiu]

#WCLC26 In DESTINY-Lung04, no OS signal yet. Toxicities led to discontinuation in 16% of both arms. Biggest concern here is the ILD at 20.8% - while most were grade 1/2 and resolved, these are still high rates. This will impact delivery and possibly subsequent therapies...

[Alessandro Di Federico @DiFedericoMD]

Identifying biomarkers to optimize treatment selection is crucial in EGFRm NSCLC.
Now fully published in @CCR_AACR, our study investigated the impact of baseline EGFR amplification & how it influences the molecular landscape at resistance to osimertinib.
https://t.co/r76D9Vd0zv

[Mark Wildgust (he/him) @MAWildgust]

Excited for the #ASCO26 plenary today and the #Proteus results! #MyCompany

https://t.co/e86qp4Pk3I

[Christine A. Garcia, MD, MPH @christinemphmd]

Striking new #lungcancer screening data:
You need to screen fewer high-risk never-smokers to catch a cancer than heavy smokers. #ASCO26 #lcsm

Number Needed to Screen (NNS):
-TALENT (Never-smokers) =150
-NELSON (Smokers) = 222
-NLST (Smokers) = 320

[J&J Innovative Medicine Global Medical Affairs @JJ_IMMedAffairs]

For US #HCPs attending @ASCO‘s 2026 annual meeting: visit us onsite at booth #15093. Click below to view the timing of our presentations. #Oncology #ASCO26​

https://t.co/q490kP6sMk

[Joshua Bauml, MD @Jbauml]

Today, the U.S. FDA approved a monthly dosing schedule for our subcutaneous treatment for patients with EGFR-mutated NSCLC. Grateful to the teams at @JNJInnovMed who made this possible.

Learn more: https://t.co/x29PLTvFnI

#MyCompany #JNJOncology

[Adam Martin @Admar2716]

@dplanchard @JCO_ASCO “a”

[FDA Drugs and Biologics @FDADrugs]

#FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection. https://t.co/6koZiqxlJE

[Oncology Brothers @OncBrothers]

Subcutaneous Amivantamab now @US_FDA approved based off #PALOMA3 study: SubQ vs. IV Ami (with Lazertinib) in EGFR+ mNSCLC.

- SubQ was non inferior to IV Ami-Laz
- Fewer IRRs with SubQ
- PFS 6.1mos (IV) & 4.3mos (SubQ). BUT OS better with SubQ (HR: 0.62) 🤔

#OncTwitter #lcsm

[Stephen V Liu, MD @StephenVLiu]

FDA approves subcutaneous amivantamab - finally! This is a no-brainer switch in my opinion. Faster, decrease risk of infusion reaction, less risk of VTE. Even possibility of greater efficacy versus IV (needs confirmation). Will switch as soon as we can.

https://t.co/NMbP93ZzgE

[Joshua Bauml, MD @Jbauml]

Today’s approval of our sub-q treatment for EGFR-mutated #NSCLC raises the standard for what patients and their loved ones can expect from the treatment experience. Proud of the @JNJInnovMed team and what this means for patients. Learn more: https://t.co/F4YDuTtDao

#JNJOncology

[NEJM @NEJM]

Original Article: Overall Survival with Amivantamab–Lazertinib in 𝘌𝘎𝘍𝘙-Mutated Advanced NSCLC (MARIPOSA phase 3 trial) https://t.co/EPke9fSkiO

Editorial: 𝘌𝘎𝘍𝘙-Mutated Lung Cancer — Letting the Butterfly Out of the Cocoon https://t.co/BZaj67XSS6

#Oncology

[Akshee Batra @AksheeBatra]

With subcutaneous amivantamab, precision oncology keeps moving forward. Our comfort with managing targeted-therapy toxicities needs to match our decades of experience with chemo! #PrecisionOncology #TargetedTherapy #EGFR #NSCLC #Amivantamab #LungCancer

[Oncology Brothers @OncBrothers]

In our “Challenging Cases” discussion on metastatic NSCLC mEGFR w/ @lungoncdoc we touch on:

✅ Rx options
✅ AE management
✅ Sequencing

Full discussion:
⭐️ https://t.co/XFMkB6kxmY
⭐️ Also on the “Oncology Brothers” podcast

#OncTwitter @OncUpdates

[Oncology Brothers @OncBrothers]

Updated data on combination options seen at #ESMO25 for metastatic non-small cell lung cancer w/ EGFR mutated disease. Stuck w/ cross trial comparisons for now! We touched on this data and our options 👇👇 with @lungoncdoc!

@EGFRSummit #OncTwitter #lcsm @OncoAlert @OncUpdates

[Stephen V Liu, MD @StephenVLiu]

Phase II study of amivantamab + lazertinib in patients with previously treated #EGFR NSCLC and brain metastases or leptomeningeal disease @JTOonline. In 20 pts with brain metastases, RR 50%, PFS 5.4m, OS 17.4m. With LMD, RR 33%, PFS 7.8m, OS 14.4m.

https://t.co/5OPkZdO32M

[Dr Rishabh Jain @DrRishabhOnco]

🧠 EGFRm NSCLC with CNS Mets? There’s new hope!

🚀 First-ever trial of amivantamab + lazertinib in:
🧩 Brain metastases (BrM)
🧩 Leptomeningeal disease (LMD)
📍 All post-osimertinib ± chemo

👨‍🔬 Results:

🧠 BrM cohort (n=20)
✅ ORR: 50%
🎯 Intracranial ORR: 40%
⏱️ PFS: 5.8 mo
❤️ OS: 17.4 mo

🧬 LMD cohort (n=21)
✅ ORR: 33%
💧 CSF CTC ↓ in 67%
⏱️ PFS: 7.8 mo
❤️ OS: 14.4 mo

🧪 MET+ tumors ➜ ORR 77% vs 26%
⚠️ Toxicities:
• Skin rash, edema → 💊 dose interruptions in 50%
• VTE risk managed with prophylactic anticoagulation 🩸

🧬 Resistance: MAPK pathway mutations (🧩 KRAS, NRAS, BRAF) in 23%

📢 Takeaway:
Feasible + active in BrM/LMD ➜ Include LMD in future trials!

📖 Chen MF et al. J Thorac Oncol. 2025.
🔗 https://t.co/65fDZbrvvv

#OncoTwitter #MedTwitter #EGFR #NSCLC #LungCancer #BrainMets @myesmo @esmo_open @IASLC @JTOonline

[NEJM @NEJM]

In advanced non–small-cell lung cancer with EGFR mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. Full MARIPOSA phase 3 trial results: https://t.co/0bliKUZzXa

#WCLC25 | @IASLC

[Yale Cancer Center @YaleCancer]

An editorial from @Sokim_33 , Drs. Katerina Politi + Sarah Goldberg emphasizes the promising activity and safety of #lazertinib in #NSCLC with uncommon EGFR mutations, supporting further study.
https://t.co/2IVGAXFJso
@SmilowCancer @YaleThoracic @yalepathology

[Stephen V Liu, MD @StephenVLiu]

Dr. @APassaroMD discusses #EGFR NSCLC at the @LungSummit. Combination therapy should now be considered our standard for first-line therapy with OS advantages seen using osi + chemo (FLAURA2) and amivantamab + lazertinib (MARIPOSA). Learning about impact on acquired resistance.